This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Miltenyi Biotec
product type :
antibody
product name :
CD178 Antibody, anti-human, APC
catalog :
130-125-980
quantity :
100 tests in 200 µL
price :
325 USD
clonality :
monoclonal
host :
mouse
conjugate :
APC
clone name :
NOK-1
The same clone is also sold as:
The same clone is also sold as:
- BioLegend: 306415, 306412, 306411, 306402, 306418, 306407, 306413, 306421, 306404, 306416, 306417, 306406, 306419
- BD Biosciences: 556373, 556372, 556374, 556371
- OriGene: AM26762PU-N, AM26762RP-N, AM26762LE-N
- Boster: M00925-2
- Invitrogen: 16-9919-81, 16-9919-85, 17-9919-42, 12-9919-42, 12-9919-41
- Exbio: 11-754-C025, 1P-754-T025, 1P-754-T100, 12-754-C100, 11-754-C100
- Abcam: ab210312
- Santa Cruz Biotechnology: sc-19681 L, sc-19681
reactivity :
human
application :
flow cytometry
citations: 1
Reference |
---|
Janssen O, Qian J, Linkermann A, Kabelitz D. CD95 ligand--death factor and costimulatory molecule?. Cell Death Differ. 2003;10:1215-25 pubmed
|
product information
MB Cataloge Number :
130-125-980
Catalog Number :
130-125-980
Product Name :
CD178 Antibody, anti-human, APC
Product Type :
Primary antibodies
Host Species :
mouse IgG1κ
Clonality :
monoclonal
Conjugation :
APC
Antigen Modification :
CD178
Clone Name :
NOK-1
Isotype :
Isotype Control Antibody, mouse IgG1
Size :
100 tests in 200 µL
US List Price :
325 USD
Product Description :
Detection of human CD178+ (Fas ligand, CD95L) cells, e.g., activated lymphocytes
ALTnames :
FASLG, ALPS1B, APT1LG1, APTL, CD95L, FasL, TNFSF6
Specificity :
human
Concentration :
1:50
Uses :
For research use only
Application Summary :
Flow cytometry
Storage :
Store protected from light at 2–8 °C. Do not freeze.
company information
Miltenyi Biotec
Friedrich-Ebert-Strae 68
51429 Bergisch Gladbach
51429 Bergisch Gladbach
macs@miltenyibiotec.com
https://www.miltenyibiotec.com1 800 FOR MACS
headquarters: Germany
questions and comments